Oppenheimer Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Edwards Lifesciences (NYSE:EW) but lowers the price target from $100 to $90.
July 25, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Edwards Lifesciences but lowers the price target from $100 to $90.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100